F-18 FDG PET/CT contributes to more accurate detection of lymph nodal metastasis from actively proliferating esophageal squamous cell carcinoma

Clinical Nuclear Medicine

Volumn 36, Issue 10, 2011, Pages 854-859

  Tanabe, Shunsuke ^a   Naomoto, Yoshio ^a   Shirakawa, Yasuhiro ^a   Fujiwara, Yasuhiro ^a   Sakurama, Kazufumi ^a   Noma, Kazuhiro ^a   Takaoka, Munenori ^a   Yamatsuji, Tomoki ^a   Hiraki, Takao ^a   Okumura, Yoshihiro ^a   Mitani, Masahiko ^b   Kaji, Mitsumasa ^c   Kanazawa, Susumu ^a   Fujiwara, Toshiyoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c Okayama Diagnostic Imaging Center   (Japan)

Author keywords

Esophageal cancer; F 18 fluorodeoxy glucose (FDG); Lymph nodal metastasis; Positron emission tomography (PET); Proliferation; Squamous cell carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; RETROSPECTIVE STUDY; TUMOR GROWTH;

CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY;

EID: 80053598556     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318217adc9     Document Type: Article

References (51)

1. Trivers KF, Sabatino SA, Stewart SL, et al. Trends in esophageal cancer incidence by histology, United States, 1998-2003. Int J Cancer. 2008;123: 1422-1428.
2. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol. 1999;26:2-8. (Pubitemid 29529530)
3. Prach AT, McDonald TA, Hopwood DA, et al. Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology? Lancet. 2007; 350:933.
4. Brooks PJ, Enoch MA, Goldman D, et al. The alcohol flushing response: an unrecognized risk factor for esophageal cancer from alcohol consumption. PLoS Med. 2009;6:258-263.
5. Lin CS, Chang SC, Wei YH, et al. Prognostic variables in thoracic esophageal squamous cell carcinoma. Ann Thorac Surg. 2009;87:1056-1065.
6. Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000;18:3202-3210.
7. van Vliet EP, Heijenbrok-Kal MH, Hunink MG, et al. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer. 2008;98:547-557. (Pubitemid 351214529)
8. Kato H, Kuwano H, Nakajima M, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer. 2002;94:921-928. (Pubitemid 34150845)
9. Kato H, Miyazaki T, Nakajima M, et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer. 2005;103:148-156. (Pubitemid 39665468)
10. Kato H, Fukuchi M, Miyazaki T, et al. Positron emission tomography in esophageal cancer. Esophagus. 2005;2:111-121. (Pubitemid 41374030)
11. Bruzzi JF, Munden RF, Truong MT, et al. PET/CT of esophageal cancer: its role in clinical management. Radiographics. 2007;27:1635-1652.
12. Jamieson GG, Thompson SK. Detection of lymph node metastasis in esophageal cancer. Br J Surg. 2008;96:21-25.
13. Kinkel K, Lu Y, Both M, et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology. 2002;224:748-756. (Pubitemid 34919808)
14. Kim K, Park SJ, Kim BT, et al. Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. Ann Thorac Surg. 2001;71:290-294. (Pubitemid 32102675)
15. Yoon YC, Lee KS, Shim YM, et al. Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection-prospective study. Radiology. 2003;227:764-770. (Pubitemid 36583034)
16. Yuan S, Yu Y, Chao KS, et al. Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med. 2006;47:1255-1259. (Pubitemid 47544876)
17. Kawarnura T, Goseki N, Koike M, et al. Acceleration of proliferative activity of esophageal squamous cell carcinoma with invasion beyond the mucosa. Cancer. 1996;77:843-849.
18. Japan Esophageal Society. Japanese Classification of Esophageal Cancer. 10th ed. Tokyo, Japan: Kanehara & Co., Ltd; 2008.
19. Fukuya T, Honda H, Hayashi T, et al. Lymph-node metastases: efficacy for detection with helical CT in patients with gastric cancer. Radiology. 1995; 197:705-711.
20. Komori T, Doki Y, Kabuto T, et al. Prognostic significance of the size of cancer nests in metastatic lymph nodes in human esophageal cancers. J Surg Oncol. 2003;82:19-27. (Pubitemid 36055487)
21. Takeuchi H, Ozawa S, Ando N, et al. Cell-cycle regulators and the Ki-67 labeling index can predict the response to chemoradiotherapy and the survival of patients with locally advanced squamous cell carcinoma of the esophagus. Ann Surg Oncol. 2003;10:792-800. (Pubitemid 40486880)
22. Himeno S, Yasuda S, Shimada H, et al. Evaluation of esophageal cancer by positron emission tomography. Jpn J Clin Oncol. 2002;32:340-346. (Pubitemid 43102786)
23. Lerut T, Flamen P, Ectors N, et al. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg. 2000;232:743-752.
24. Bruzzi JF, Truong MT, Marom EM, et al. Incidental findings on integrated PET/CT that do not accumulate F-18 FDG. Am J Roentgenol. 2006;187: 1116-1123. (Pubitemid 44453971)
25. Miyata H, Doki Y, Yasuda T, et al. Evaluation of clinical significance of 18F-fluorodeoxyglucose positron emission tomography in superficial squamous cell carcinomas of the thoracic esophagus. Dis Esophagus. 2008;21: 144-150. (Pubitemid 351247327)
26. Mu DB, Wang SP, Yang WF, et al. Correlation between FDG PET /CT and the expression of glutl and ki-67 antigen in esophageal cancer. Zhonghua Zhong Liu Za Zhi. 2007;29:30-33.
27. Youssef EM, Matsuda T, Takada N, et al. Prognostic significance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the esophagus. Cancer. 1995;76:358-366.
28. Kato H, Nakajima M, Sohda M, et al. The clinical application of F-18-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer. 2009;115: 3196-3203.
29. Nishihira T, Hirayama K, Mori S, et al. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg. 1998;175:47-51. (Pubitemid 28047029)
30. Peyre CG, Hagen JA, DeMeester SR, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008;248:549-556.
31. Altorki NK, Zhou XK, Stiles B, et al. Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg. 2008;248:221-226.
32. Fujita H, Kakegawa T, Yamana H, et al. Lymph node metastasis and recurrence in patients with a carcinoma of the thoracic esophagus who underwent three-field dissection. World J Surg. 1994;18:266-272. (Pubitemid 24126036)
33. Shiozaki H, Yano M, Tsujinaka T, et al. Lymph node metastasis along the recurrent nerve chain is an indication for cervical lymph node dissection in thoracic esophageal cancer. Dis Esophagus. 2001;14:191-196. (Pubitemid 34170807)
34. Ueda Y, Shiozaki A, Itoi H, et al. Intraoperative pathological investigation of recurrent nerve nodal metastasis can guide the decision whether to perform cervical lymph node dissection in thoracic esophageal cancer. Oncol Rep. 2006;16:1061-1066.
35. Miyata H, Yano M, Doki Y, et al. A prospective trial for avoiding cervical lymph node dissection for thoracic esophageal cancers, based on intraoperative genetic diagnosis of micrometastasis in recurrent laryngeal nerve chain nodes. J Surg Oncol. 2006;93:477-484. (Pubitemid 44651271)
36. Veeramachaneni NK, Zoole JB, Decker PA, et al. Lymph node analysis in esophageal resection: American College of Surgeons Oncology Group Z0060 trial. Ann Thorac Surg. 2008;86:418-421. (Pubitemid 351978043)
37. Greenstein AJ, Litle VR, Swanson SJ, et al. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer. 2008;112:1239-1246. (Pubitemid 351429738)
38. Pfau PR, Perlman SB, Stanko P, et al. The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography. Gastrointest Endosc. 2007;65:377-384.
39. Choi JY, Lee KH, Shim YM, et al. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nucl Med. 2000;41:808-815. (Pubitemid 30266024)
40. Higuchi I, Yasuda T, Yano M, et al. Lack of fluorodeoxyglucose F-18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2008;1369:205-212.
41. Roedl JB, Halpern EF, Colen RR, et al. Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus. Mol Imaging Biol. 2009;11: 54-60.
42. Choi JY, Jang HJ, Shim YM, et al. F-18-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications. J Nucl Med. 2004;45:1843-1850.
43. Suzuki H, Hasegawa Y, Terada A, et al. Limitations of FDG-PET and FDG-PET with computed tomography for detecting synchronous cancer in pharyngeal cancer. Arch Otolaryngol Head Neck Surg. 2008;134:1191-1195.
44. van Westreenen HL, Westerterp M, Jager PL, et al. Synchronous primary neoplasms detected on F-18-FDG PET in staging of patients with esophageal cancer. J Nucl Med. 2005;46:1321-1325. (Pubitemid 43733482)
45. Teyton P, Metges JP, Atmani A, et al. Use of positron emission tomography in surgery follow-up of esophageal cancer. J Gastrointest Surg. 2009;13:451-458.
46. Kato H, Miyazaki T, Nakajima M, et al. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma. Br J Surg. 2004;91:1004-1009. (Pubitemid 39070815)
47. Duong CP, Demitriou H, Weih L, et al. Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer. Eur J Nucl Med Mol Imaging. 2006;33:759-769. (Pubitemid 43979683)
48. Chatterton BE, Ho Shon I, Baldey A, et al. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging. 2009;36:354-361.
49. van Westreenen HL, Heeren PA, Jager PL, et al. Pitfalls of positive findings in staging esophageal cancer with F-18-fluorodeoxyglucose positron emission tomography. Ann Surg Oncol. 2003;10:1100-1105. (Pubitemid 40486835)
50. Croft DR, Trapp J, Kernstine K, et al. FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence. Lung Cancer. 2002;36:297-301. (Pubitemid 34497130)
51. Mackie GC, Pohlen J. Mediastinal histoplasmosis: F-18 FDG PET and CT findings simulating malignant disease. Clin Nucl Med. 2005;30:633-635. (Pubitemid 41216163)